Giannelos Nikolaos, Curran Desmond, Nguyen Chi, Kagia Carol, Vroom Nikki, Vroling Hilde
GSK, Wavre, Belgium.
Pallas Health Research & Consultancy, a P95 Company, Leuven, Belgium.
Infect Dis Ther. 2024 Jul;13(7):1461-1486. doi: 10.1007/s40121-024-01002-4. Epub 2024 Jun 19.
The objective of this work was to summarize the incidence of herpes zoster (HZ) complications in different populations.
Systematic literature review of PubMed, Embase, and Virtual Health Library records between January 1, 2002 and October 20, 2022 using search strings for HZ, complications, and frequency measurements.
The review included 124 studies, most conducted in the general population (n = 93) and on individuals with comorbidities (n = 41) ≥ 18 years of age. Most studies were conducted in Europe (n = 44), Asia (n = 40), and North America (n = 36). Postherpetic neuralgia (PHN) was the most studied neurological complication. Variable relative PHN incidence was found in the general population (2.6-46.7%) or based on diagnosis: immunocompromised (3.9-33.8%), depression (0-50%), and human immunodeficiency virus (HIV) (6.1-40.2%). High incidence rates were observed in hematological malignancies (HM) and solid organ malignancies (132.5 and 93.7 per 1000 person-years, respectively). Ocular complications were frequently reported with herpes zoster ophthalmicus (HZO). The relative incidence (incidence rate) of HZO in the general population was reported as 1.4-15.9% (0.31-0.35 per 1000 person-years). High relative incidence was observed in HIV (up to 10.1%) and HM (3.2-11.3%). Disseminated HZ was the most frequently reported cutaneous complication. The relative incidence of disseminated HZ was 0.3-8.2% in the general population, 0-0.5% in the immunocompetent, and 0-20.6% in patients with comorbidities. High relative incidence was reported in HM and solid organ transplant (up to 19.3% and 14.8%, respectively).
Most reported complications were neurological (n = 110), ocular (n = 48), and cutaneous (n = 38). Few studies stratified complications by age or gender (or both). Incidence appeared higher in select immunocompromised populations. Higher incidence was associated with older age in several studies; the general association with gender was unclear.
Variable incidence of HZ complications was reported by population subgroup. Further research is required to quantitatively analyze incidence by age, gender, and location.
本研究的目的是总结不同人群中带状疱疹(HZ)并发症的发生率。
对2002年1月1日至2022年10月20日期间PubMed、Embase和虚拟健康图书馆记录进行系统文献综述,使用关于HZ、并发症和频率测量的检索词。
该综述纳入了124项研究,大多数研究是在≥18岁的普通人群(n = 93)和合并症患者(n = 41)中进行的。大多数研究在欧洲(n = 44)、亚洲(n = 40)和北美(n = 36)开展。带状疱疹后神经痛(PHN)是研究最多的神经并发症。在普通人群中(2.6 - 46.7%)或根据诊断发现PHN的相对发生率存在差异:免疫功能低下者(3.9 - 33.8%)、抑郁症患者(0 - 50%)和人类免疫缺陷病毒(HIV)感染者(6.1 - 40.2%)。血液系统恶性肿瘤(HM)和实体器官恶性肿瘤患者中观察到高发病率(分别为每1000人年132.5例和93.7例)。眼部并发症在眼部带状疱疹(HZO)中经常被报道。普通人群中HZO的相对发生率(发病率)报告为1.4 - 15.9%(每1000人年0.31 - 0.35例)。在HIV感染者(高达10.1%)和HM患者(3.2 - 11.3%)中观察到较高的相对发生率。播散性HZ是最常报道的皮肤并发症。普通人群中播散性HZ的相对发生率为0.3 - 8.2%,免疫功能正常者为0 - 0.5%,合并症患者为0 - 20.6%。HM患者和实体器官移植患者中报告了较高的相对发生率(分别高达19.3%和14.8%)。
大多数报告的并发症为神经方面(n = 110)、眼部(n = 48)和皮肤方面(n = 38)。很少有研究按年龄或性别(或两者)对并发症进行分层。在特定免疫功能低下人群中发病率似乎更高。在几项研究中,较高的发病率与年龄较大有关;与性别的总体关联尚不清楚。
不同人群亚组中HZ并发症的发生率存在差异。需要进一步研究按年龄、性别和地点对发病率进行定量分析。